The present invention relates to harringtonine, homoharringtonine and/or derivatives thereof, in particular compounds of formula 1a to 1g as defined in table 1, more particularly in the form of salt, preferably crystalline salt, for use in the treatment or prevention of breast cancer, in particular triple-negative breast cancer (TNBC).
